Eli Lilly and Co (LLY)
797.45
+21.07
(+2.71%)
USD |
NYSE |
Nov 07, 16:00
802.31
+4.86
(+0.61%)
Pre-Market: 04:45
Eli Lilly Revenue (TTM): 40.86B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.86B |
| June 30, 2024 | 38.92B |
| March 31, 2024 | 35.93B |
| December 31, 2023 | 34.12B |
| September 30, 2023 | 32.07B |
| June 30, 2023 | 29.52B |
| March 31, 2023 | 27.69B |
| December 31, 2022 | 28.54B |
| September 30, 2022 | 29.24B |
| June 30, 2022 | 29.07B |
| March 31, 2022 | 29.32B |
| December 31, 2021 | 28.32B |
| September 30, 2021 | 27.76B |
| June 30, 2021 | 26.73B |
| March 31, 2021 | 25.49B |
| December 31, 2020 | 24.54B |
| September 30, 2020 | 23.21B |
| June 30, 2020 | 22.95B |
| March 31, 2020 | 23.09B |
| December 31, 2019 | 22.32B |
| September 30, 2019 | 21.84B |
| June 30, 2019 | 21.67B |
| March 31, 2019 | 21.62B |
| December 31, 2018 | 21.49B |
| September 30, 2018 | 19.12B |
| Date | Value |
|---|---|
| June 30, 2018 | 19.47B |
| March 31, 2018 | 19.71B |
| December 31, 2017 | 19.97B |
| September 30, 2017 | 22.47B |
| June 30, 2017 | 22.00B |
| March 31, 2017 | 21.59B |
| December 31, 2016 | 21.22B |
| September 30, 2016 | 20.84B |
| June 30, 2016 | 20.61B |
| March 31, 2016 | 20.18B |
| December 31, 2015 | 19.96B |
| September 30, 2015 | 19.70B |
| June 30, 2015 | 19.62B |
| March 31, 2015 | 19.58B |
| December 31, 2014 | 19.62B |
| September 30, 2014 | 20.30B |
| June 30, 2014 | 21.20B |
| March 31, 2014 | 22.19B |
| December 31, 2013 | 23.11B |
| September 30, 2013 | 23.26B |
| June 30, 2013 | 22.93B |
| March 31, 2013 | 22.60B |
| December 31, 2012 | 22.60B |
| September 30, 2012 | 22.69B |
| June 30, 2012 | 23.40B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
22.32B
Minimum
Dec 2019
40.86B
Maximum
Sep 2024
28.98B
Average
28.43B
Median
Revenue (TTM) Benchmarks
| Amgen Inc | 32.53B |
| Johnson & Johnson | 87.70B |
| Merck & Co Inc | 63.17B |
| Viking Therapeutics Inc | -- |
| Moderna Inc | 4.988B |